No Detail Found!

Cancer treatment: what's ahead?

Author(s)
Tariq Parvez Department of Radiology, King Fahad Hospital, Madina Munawara, Kingdom of Saudi Arabia.
Abstract
Surgery, chemotherapy, and radiation therapy are standard modalities for cancer treatment. Biological therapy (immunotherapy, biotherapy, or biological response modifier therapy) is a comparatively novel addition to this armamentarium. Biological therapies use the body’s immune system, either directly or indirectly, to fight cancer or to lessen the side effects that may be caused by some cancer treatments. Biological therapeutic agents include interferons, interleukins, colony-stimulating factors, monoclonal antibodies, vaccines, gene therapy, and nonspecific immunomodulating agents. A promising form of cancer treatment is immunotherapy. Immunotherapy for cancer is essentially the stimulation of the immune system through a variety of reagents such as vaccines, infusion of T-cells, or cytokines. These reagents act through one of several mechanisms including stimulating the anti-tumor response, decreasing suppressor mechanisms, altering tumor cells to increase their immunogenicity and making them more susceptible to immunologic defenses, and improving tolerance to cytotoxic agents or radiotherapy. This review describes some novel approaches in the immunotherapy in cancer.
Publication Details
Page(s) 738-745
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 15, Issue: 11, Year: 2005

Request the full text from PASTIC

Keywords
Antibodies, Viruses, Immunotherapy, T-Cell, Dendritic cells Cancer vaccine, Tumor antigen, Biological therapy
References
.2001 .. ApplicatioonftheIFN-gammaELISPOT assaytoquantif cellresponseasgainstprotein/s.Immunol Methods, 247 : 17-24.
.2001 .High-doseinterferaolnfa-2bsignifica prolongrselapse-fraened overalslurvivaclomparedwitht GM2-. vaccinein patientwsithresectesdtageIIBmelanoma:resultosf intergroturpialE1694/S9512/050980 J Clin Oncol, 19 : 2370-80.
Maus MV,Nepom GT,June CH .2003 .HLA tetramer-baasretdificiaanltigen-presencteilnlgfsorstimulatioofn CD4+T-cellsC. lin Immunol, 106 : 16-22.
Lu J .2002 .Interleukina-n2. CelisE. Recognitioonfprostattuemocrellsby cytotoxi lymphocytespecificforprostate-specmifeicmbraneantig Cancer Res, 62 : 5807-12.
.2002 .Epstein-Barvrirus-associated interleukin-i1m5m:unotherafpoy rcancerC. ytokine Growth Factor Rt cancerse:tiologanydtreatmeHnetrp.es, 13 : 169-83.
.2004 .. Curr Opin Immunol, 16 : 130-6.
.2003 .Chemotherapaynd newtrendisn treatmeonftadvancedstagenon-small-cleulnlg cancerJ. CollPhysicians SurgPak, 13 : 483-90.
.2000 .Physician relateddelayi diagnosi(scasereporCto)l. SurgPak, 10 : 116-9.
Lee P .2001 .. Clin Oncol, 15 : 3836-47.
.2003 .. ub Med Coll, 15 : 65-8.
.2002 .and acquisitioonftumoresistancteocelldeath. Tissue Antigens, 60 : 273-81.
.2001 .. wdotumoresvadeimmunesurveillanEcuer?jMedRes, 6 : 323-32.
Mintz P .2001 .. lin Invest, 107 : 477-84.
.2004 .. rr Drug Targets, 5 : 17-39.
Chen I . .Wong-Sta a,1 Generatioonfdendriticellsfromlentivirvaelctor-trans CD34+ cellsfromHIV+ donorJsM. , 70 : 183-6.
.2002 .. ol Cancer Res Treat, 1 : 65-9.
Langlade-DemoyePn. .2002 .tracel immuneresponsaegainsatcutelymphoblastliecukemiacells. munolRev, 188 : 65-80.
Lynch T,Mihm M . .Vaccinationwith irradiateadutologomuselanomacells engineeretdosecretheumangranulocyte-macropchoalgoen­ y stimulatifnagctogreneratpeostenatntitumoimrmunityin patients withmetastatmicelanomaP. rocNatlAcadSd USA1998, 95 : 13141-6.
.2003 .. SaludPublicaMex, 45(suppl3) : S443-8.
Sapp M,Desai H .2003 .. SaludPublica Mex, 45(suppl3) : S437-42.
.2003 .Migratioonfhumandendriticcellsafteirnjectioinn amongchildrenfollowinugniversahlepatitisB immunization. Liver Int, 23 : 309-14.
.2002 .Associatioonfsocialclassin HbsAG and Transimmunizatioannd the evolutionof extracorporeal hepatocellucalarrcinom]aC. fus Apheresis Sci, 26 : 181-90.
.1997 .DiffereTnt helpercelltypesand antibodiysotypegseneratebdy salineand genegunDMA immunizatiojnlm. , 158 : 2278-84.
Ye W,Yee R .2003 .Humorailmmuneresponsteoa therapeutpioclyvalecnatncer vaccineaftecrompletreesectioonfthickprimarmy elanomand sentinellymphadenectomJyC. lin Oncol, 21 : 313-9.
Yee R,He LZ .2001 .an allogenetiucmorcellvaccine,inducesspecific humoraland cellulaimrmune responseisn advancedcolon 55. nn Surg Oncol, 8 : 389-401.
.1997 .Dendritic cell-based immunotherapyof cancer with. metastaseJsC.lin Oncol, 15 : 2359-70.
A-A24-restricteCdTL MN,RosesDF. MN .2001 .-antigen, epitope:clinicaloutcomesof 18 patientswith metastatic melanomvaaccine. Clin Cancer Res, 24 : 909-17.
.2003 .Strategiefsorthe developmenotf PSA-based vaccinesforthe treatmenotf advancedprostactaencerE. xpert Rev Vaccines, 2 : 483-93.
.2002 .. tCurr opin Investig Drugs, 3 : 140-9.
.2004 .Immune responsteopostsurgicaadljuvanatctive immunotherapwyith Canvaxinpolyvalencatncervaccine: correlatiownisth clinicalcourseof patientwsithmetastatic melanomaD. ev Biol, 116 : discussio2n29-36.
Groot MT,BonselGJ MT .2005 .ImmunotherawpyithautologotuusmocrellBCG vaccinein patientwsithcoloncancera: prospectisvteudyof 58. MotlSE. ccine, 23 : 2379-87.
.2004 .. Opin Mol Ther, 6 : 40-7.
0

Citations

0

Downloads

67

Views